Antidepressant Withdrawal vs Relapse: Why Estimates Differ and Timing Matters

The short answer

Symptoms after stopping or reducing an antidepressant do not automatically mean the original depression or anxiety has returned. Withdrawal is another possibility, and the two can overlap. There is no single symptom or calendar cutoff that reliably settles every case. A careful clinical review considers timing, the kind of symptoms, medication history and the broader course. [1,2]

Recent meta-analyses report different estimates. That disagreement should be explained rather than resolved by choosing the most reassuring or most alarming number. Raw symptom incidence, symptoms beyond a comparison condition and the average number of symptoms are different outcomes. [1,2,3]

What the 2024 incidence review measured

The review of 79 studies included randomized and observational data involving more than 21,000 participants. The authors estimated symptom incidence after antidepressant and placebo discontinuation separately. The paper has a linked published correction whose full contents could not be verified for this review; precise pooled percentages from that report are therefore withheld here. Its distinction between raw symptoms and symptoms beyond a comparison background remains important. [1,5]

An estimate adjusted for comparison-group symptoms is not the same as the total proportion who noticed anything. It also does not classify every background symptom as imaginary: people can experience real symptoms for reasons other than pharmacological withdrawal, including expectation, ordinary illness or recurrence. A comparison helps estimate attribution at group level, not determine whether an individual's distress is legitimate. [1]

Pooling different drugs, durations, schedules and measurement methods leaves substantial heterogeneity. A combined proportion should not be presented as a precise personal risk for someone taking one medication for many years. [1]

What the later randomized-data review adds

The 2025 review examined randomized comparisons using standardized scales and individual symptoms. It found a small average increase in discontinuation symptoms at one week, roughly equivalent to one additional symptom on a commonly used scale. Dizziness and some other physical symptoms were particularly relevant. [2]

An average is not a ceiling. A small mean can coexist with a subgroup having substantial symptoms, and early assessments may not fully represent delayed or prolonged difficulties. The review's methods answer a valuable question about average short-term burden in included trials without settling every long-term clinical experience. [2]

Likewise, absence of an average increase in depressive symptoms at a particular early point does not prove that relapse never occurs later. The distinction between withdrawal and recurrence needs its own follow-up and assessment.

A disclosure correction belongs in the interpretation

The 2025 randomized-data review has a published correction adding a coauthor's omitted disclosures, including personal fees from numerous commercial organizations and research grants. The correction concerns transparency rather than a new estimate of symptom burden. Such relationships do not automatically invalidate the analysis, but readers should have them when assessing interpretation and the need for independent scrutiny. [4]

Why another review found a higher proportion

The separate incidence review reported a pooled withdrawal-syndrome proportion around 43%, using a different body of studies and definitions. It also noted that many studies involved relatively short medication exposure and brief follow-up. [3]

This estimate cannot simply be placed beside the placebo-adjusted figure as if the two were competing measurements of exactly the same population and endpoint. One can ask how many people report a syndrome under a given definition; another can ask how much more often symptoms occur than in a comparison group. [1,3]

The tapering subgroup comparison in that review did not show a statistically clear difference, but this is not proof that abrupt stopping is equally safe or that all taper methods are equivalent. Heterogeneous observational or subgroup comparisons cannot determine a personalized schedule. [3]

Clues are useful without becoming rules

The onset of new symptoms after a reduction, physical symptoms unlike the original illness and a clear relationship to missed doses may make withdrawal more plausible. A gradual return of the original syndrome may suggest recurrence. In practice, those patterns overlap and can be complicated by sleep, stress, substances and other treatment changes. [1,2]

A timeline is often more useful than a diagnostic argument. Record approximate dose changes, missed doses, symptom onset and any symptoms that differ from the previous condition. Include functioning and safety, not only a checklist score. Avoid changing several things at once without medical guidance because that makes interpretation more difficult.

Improvement after a medication change is also clinical information rather than absolute proof of one explanation. Treatment decisions should consider the overall pattern and the risks of further changes.

What the evidence cannot prescribe

None of these reviews establishes one taper schedule for every drug or every duration of use. Tablet availability, formulation, prior withdrawal experiences and concurrent conditions can affect planning. The relevant question is not whether tapering is morally necessary, but what approach is clinically appropriate and feasible. [1,2,3]

Do not abruptly stop, alternate doses or substitute supplements based on this article. If symptoms emerge during a planned change, contact the prescriber to review the plan. Severe agitation, suicidal intent, confusion, mania-like symptoms or inability to remain safe warrant urgent help rather than waiting for a routine review.

Severity and duration must not disappear into incidence

The proportion reporting at least one symptom does not tell us how disabling that symptom was, how long it lasted or what assistance was needed. Conversely, a study designed to measure a defined syndrome can miss milder symptoms while still answering a useful question about that syndrome. These outcomes should be reported alongside each other rather than treated as interchangeable estimates. [1,2,3]

Brief trial follow-up can also create an uneven view of the problem. It may capture early physical symptoms well while leaving later persistence or recurrence uncertain. People with long prescribing histories may be underrepresented. A clinician should therefore use the pooled evidence as context, listen to the actual course and avoid either dismissing a severe experience because the average was modest or assuming every symptom must be withdrawal because a higher estimate exists. [1,2]

Better research and better conversations

Future studies need longer and clearer follow-up, consistent definitions and better representation of people with long treatment histories. They should distinguish new withdrawal symptoms, persistence of the original condition, recurrence and adverse events. Severe and prolonged experiences need direct study rather than being inferred from the overall mean.

For a patient, an honest conversation can hold both sides: antidepressants may have provided important benefit, and stopping can produce difficulties that deserve careful attention. Recognizing withdrawal does not mean medication was always harmful; recognizing relapse risk does not mean every post-discontinuation symptom is illness returning. [1,2,3]

How to read this review

This is a critical narrative synthesis of selected published research, including reviews and meta-analyses where available, not a new statistical meta-analysis. It is not an exhaustive systematic search, an individual diagnosis or a treatment prescription. Source identities and abstracts were checked against Europe PMC records indexed from PubMed on October 26, 2026. Abstract-level verification does not establish every detail of full-text methods, adverse-event reporting, corrections or investigator conflicts. Those gaps limit confidence rather than supplying permission to assume favorable results.

A reference number links an explanation to its source; a PubMed identifier locates a publication and is not a quality score. Studies reanalyzed in several reviews are still the same underlying participants. Clinical recommendations, observational associations and randomized treatment comparisons answer different questions. Where the evidence concerns a mixed diagnostic group, this review does not present that average as an established result for every diagnosis. No affiliate products are ranked here.

For related research, see emotional numbness anhedonia blunting, persistent depressive disorder dysthymia. Browse the mental-health research library for the complete collection.